Molinar

Quick links to important sections

Molinar

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Molinar

Molinar is a pharmaceutical preparation that delivers the essential nutrient Colecalciferol (Vitamin D3), categorized as both a fat-soluble vitamin and a crucial prohormone. Its fundamental role is to ensure the body can properly absorb and utilize essential minerals for skeletal and general systemic health.

Property Description
Active ingredient Colecalciferol (Cholecalciferol, Vitamin D3)
Form Oral preparations (e.g., capsules, tablets, liquid drops)
Pharmacological class Vitamin D Analog / Fat-Soluble Vitamin
General purpose Supports mineral homeostasis; prevents Vitamin D insufficiency
Origin Exogenous (supplemental) or Endogenous (skin-synthesized)

The Identity of Molinar: A Vitamin D Analog and Prohormone

Molinar contains the active substance Colecalciferol, which is chemically defined as a secosteroid and is classified within the Vitamin D Analog pharmacological group. Unlike many vitamins that act directly, Colecalciferol functions as an essential prohormone, meaning it must be metabolized sequentially in the body—first in the liver and then the kidneys—into its potent hormonal form, calcitriol. This metabolic requirement underpins its role as a precursor vital for hormone system regulation and is clinically recognized as the key step in achieving Vitamin D's systemic effects.


Composition and Core Purpose: Supporting Mineral Homeostasis

As a fat-soluble vitamin, Colecalciferol is commonly supplied in various oral preparations, including capsules and liquid drops often suspended in an oily vehicle to maximize stability and assimilation. Its core purpose is to regulate the body's mineral environment. Maintaining adequate Colecalciferol levels is essential for promoting the intestinal absorption of calcium and phosphate from the diet. This physiological action is indispensable because it ensures the body has the necessary building blocks for bone mineralization, ultimately maintaining strong, healthy bones and supporting overall mineral homeostasis.

What side effects are possible with Molinar?

Possible Side Effects and Safety Information

The safety profile of Molinar (molnupiravir) is based on clinical trial data and post-authorization experience, which identifies specific adverse reactions and outlines critical restrictions.

Adverse Reactions

Adverse reactions are organized by the body system affected and their reported frequency in clinical trials:

  • Common Adverse Reactions (occurring in 1% or more of patients in clinical trials):
    • Gastrointestinal Disorders: Diarrhea, Nausea.
    • Nervous System Disorders: Dizziness, Headache.
  • Serious Adverse Reactions: Hypersensitivity reactions, including anaphylaxis, have been reported during post-authorization use. If signs or symptoms of a clinically significant hypersensitivity reaction occur, the medicine must be discontinued immediately.

Safety Restrictions and Population-Specific Warnings

Official regulatory documents contain several restrictions based on pre-clinical data and known risks:

  • Pediatric Restriction: Molinar is not authorized for use in individuals younger than 18 years of age. This restriction is due to concerns regarding potential adverse effects on bone and cartilage growth observed in animal studies.
  • Embryo-Fetal Toxicity: Based on findings from animal reproduction studies, the medicine may cause fetal harm and is not recommended for use during pregnancy.
    • Contraception Requirements: Females of childbearing potential are advised to use effective contraception during treatment and for at least 4 days after the last dose. Males with partners of childbearing potential are advised to use effective contraception during treatment and for at least 3 months after the last dose, due to a lack of complete data on the drug’s potential effect on sperm.
  • Lactation: Breastfeeding is not recommended during treatment and for 4 days after the final dose.
  • Duration Limit: The medicine is not authorized for use for longer than 5 consecutive days, as safety and efficacy beyond this duration have not been established.

These official safety statements govern the appropriate use of the medicine by explicitly defining populations for whom the risk is not acceptable, mandating risk mitigation measures (contraception), and classifying the nature and frequency of adverse events.

Overdose and Emergency Response

Overdose of Molinar, which delivers Colecalciferol (Vitamin D3), results in a condition officially documented as Hypervitaminosis D, characterized by persistent and dangerous Hypercalcemia (elevated serum calcium levels). The officially listed manifestations of toxicity typically involve multiple organ systems.

Documented presentations include gastrointestinal disturbances such as nausea, vomiting, and loss of appetite, alongside systemic symptoms like fatigue, excessive thirst (polydipsia), and frequent urination (polyuria). Neurological signs such as apathy and confusion are also officially noted. Authorities classify severe hypercalcemia as a potentially life-threatening medical emergency. Documented risks include major organ damage, particularly irreversible renal damage (nephrocalcinosis) and generalized vascular and soft-tissue calcification.

Immediate medical help must be sought if any symptoms of overdose are suspected. The regulatory mandate is to immediately discontinue Molinar and any other sources of Vitamin D. Management, for which no specific antidote is known, is symptomatic and supportive, focusing on measures to urgently correct the hypercalcemia. Close monitoring of serum calcium and renal function is required. A specific regulatory caution notes the risk of fetal harm, including mental retardation and cardiovascular defects, if overdose occurs during pregnancy.

Therapeutic Uses of Molinar

What Molinar Treats: Main Uses and Benefits

Molinar is relevant when supportive symptom management is appropriate, primarily applied across domains where additional symptomatic support is needed. It may be part of symptomatic management in situations involving distressing symptoms associated with acute or disruptive episodes.

Molinar is commonly used to help manage symptoms in conditions involving episodic or fluctuating manifestations that may intensify temporarily. This medication helps address symptom clusters that may become intense or disruptive, such as those that interfere with daily comfort or create noticeable physiological strain. The overall therapeutic benefit contributes to easing the overall symptom load during periods of heightened symptoms.

Commonly managed indications include conditions marked by increased physiological stress, conditions where symptoms escalate temporarily, and conditions where functional stability may be affected.

“This medication is applied across therapeutic domains where short-term symptom management is appropriate, and may help patients cope more steadily with symptom fluctuations.”


Quick Fact: Supports management of Disruptive Symptoms


Eligibility and Restrictions for Use

The eligibility for using Molinar (Colecalciferol) is strictly defined by regulatory documents, focusing on existing physiological conditions and age groups.

Populations Prohibited From Use

Use is contraindicated and must be avoided in patients with:

  • Hypercalcaemia (high blood calcium levels) or Hypercalciuria (high urine calcium levels).
  • Hypervitaminosis D (existing vitamin D toxicity).
  • Severe Renal Impairment (due to the kidney’s role in metabolizing Colecalciferol).
  • Nephrolithiasis (calcium kidney stones) or Nephrocalcinosis (calcium deposits in the kidneys).
  • Known Hypersensitivity to the active substance or excipients.

Conditional Use and Restrictions

Population Category Regulatory Eligibility Status
Impaired Renal Function Use requires caution and monitoring of calcium/phosphate levels.
Sarcoidosis Use requires caution due to a documented risk of hypercalcaemia.
Hepatic Impairment No dose adjustment is typically required.
Children under 12 Specific high-strength formulations are not recommended; specialized pediatric forms are required.

Pregnancy and Lactation Eligibility

Use during pregnancy is permitted only when strictly indicated to correct deficiency, and the use of high therapeutic doses is restricted due to the potential risk of fetal abnormalities. The medicine is excreted in breast milk, and while use is generally compatible with maintenance doses, maternal high-dose regimens require close monitoring of the breastfed infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Molinar (Colecalciferol) is defined by officially documented pharmacokinetic and pharmacodynamic patterns, as outlined in government regulatory information. All interaction restrictions are based on formal outcomes and not clinical advice.

Documented Drug-Drug and Substance Interactions

Interaction Type Interacting Substances/Classes Formal Interaction Outcome
Reduced Absorption Bile Acid Sequestrants (e.g., Cholestyramine), Certain Laxatives (e.g., Mineral Oil), Orlistat Impair the intestinal uptake of the fat-soluble Colecalciferol, reducing systemic exposure.
Increased Catabolism Anticonvulsants (e.g., Phenytoin, Phenobarbital), Antifungal medicines Accelerate the metabolic breakdown of Colecalciferol, resulting in lower plasma levels.
Pharmacodynamic Thiazide Diuretics (e.g., Bendroflumethiazide), Cardiac Glycosides Thiazides cause hypercalcemia; this additive effect may precipitate cardiac arrhythmias in patients using Cardiac Glycosides.

Restrictions and Population Notes

Co-administration with other Vitamin D or high-level Calcium/Phosphate supplements is restricted by regulatory bodies due to the risk of excessive systemic accumulation, such as hypercalcemia. For patients with renal dysfunction (specifically those on chronic dialysis), co-administration with magnesium-containing products increases the documented risk of hypermagnesemia. No mandatory timing separation rules are explicitly documented for Colecalciferol alone.

Mechanism of Action

Targeted Enzyme Inhibition (PDE3)

Molinar's primary effect is initiated by its ability to inhibit the enzyme phosphodiesterase type 3 (PDE3), which is essential for degrading the cellular messenger cyclic AMP (cAMP) in cardiac myocytes and vascular smooth muscle cells. This direct interference with the enzyme initiates a molecular cascade that modifies the rate of cAMP degradation.

Enhanced Intracellular Signaling and Calcium Flux

By inhibiting PDE3, the drug increases the intracellular concentration of cAMP. This enhanced signaling activates downstream proteins that change the handling of calcium ions inside the heart muscle cells. This action results in greater calcium availability for the contractile proteins, leading to enhanced myocardial contractility.

Integrated Cardiovascular Modulation

Simultaneously, the increase in cAMP concentration in blood vessel walls promotes smooth muscle relaxation. The resulting dual physiological action—enhanced myocardial contractility and concurrent smooth muscle relaxation in the vasculature (vasodilation)—provides the combined modulation of circulatory dynamics associated with the mechanism.

Dosage and Administration Information

How to Use Molinar: Administration Guidelines

The usage of Molinar (Colecalciferol, Vitamin D3) is guided by standardized instructions detailing the route, dosage patterns, and specific timing requirements. The approved route of administration for Molinar is oral, available in forms such as capsules, tablets, and liquid drops.


Dosing and Frequency Patterns

Administration follows a typical two-phase cycle: an initial loading phase for correction and a subsequent maintenance phase. The loading phase may involve high doses, such as 20,000 IU or 50,000 IU administered once weekly for a period of several weeks. The long-term maintenance phase uses lower daily doses, generally ranging from 800 IU to 2,000 IU once daily. These numerical regimens define the standard protocol for use.


Procedural and Population-Specific Conditions

Due to Colecalciferol’s status as a fat-soluble vitamin, instructions direct that the medication be taken with food, preferably the largest meal of the day, to maximize absorption. For liquid formulations, accurate administration requires the use of a calibrated measuring device provided in the package. If a dose is missed, it should be taken as soon as remembered, but a double dose must not be taken to make up for the skipped one. Additionally, Molinar should not be used in patients with severe renal impairment and high-strength preparations are generally not recommended for children under 12 years.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Molinar (Colecalciferol)

The research on Molinar (Colecalciferol) primarily consists of controlled clinical trials and large-scale reviews focused on its fundamental context in mineral balance and correcting deficiency. The findings describe group patterns and contribute to the broader evidence landscape, but research does not determine whether an individual will respond similarly.

Evidence for Correcting Primary Vitamin D Deficiency

Studies exploring primary Vitamin D deficiency (a low concentration of the 25( OH) D biomarker in the blood) have primarily used Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies focused on populations with deficiency, ranging from mild insufficiency to severe deficiency. Trials documented a measurable increase in the key 25( OH) D biomarker during the study period following the administration of Colecalciferol. Research describes how different dosing regimens were evaluated in relation to the rate at which target levels were measured. What remains uncertain is the establishment of a single, universally accepted 25( OH) D level that defines optimal sufficiency for every individual.

Evidence for Use in Supporting Bone and Skeletal Health

The role of Molinar in the prevention of deficiency diseases like rickets in children and osteomalacia in adults is based on historical clinical evidence and widely adopted public health data. Because this is considered a fundamental established use, large-scale, placebo-controlled RCTs are generally considered clinically inappropriate in severely deficient groups.

Studies on Fracture Incidence and Bone Mineral Density

Research exploring the incidence of skeletal fractures was evaluated in large-scale, long-term RCTs, predominantly involving older adults and postmenopausal women. Outcomes monitored included the rate of hip and non-vertebral fractures. In populations identified with lower baseline Vitamin D status, studies observed patterns where the administration of Colecalciferol, particularly in combination with calcium, was associated with lower reported fracture events. Conversely, in groups of community-dwelling individuals who were not deficient at the start, evidence suggests that findings were mixed regarding any association between Vitamin D supplementation alone and fracture rate.

Key Studies & References

  1. Effect of Vitamin D Supplementation on Risk of Fractures and Falls According to Dosage and Interval: A Meta-Analysis
  2. Cholecalciferol (Vitamin D3): MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Molinar (FAQ)

Q: How quickly does Molinar typically start to work?

Information found in the official Clinical Pharmacology section of the drug's label addresses how quickly Molinar begins to work. This measured onset of action describes the expected time frame needed for the active substance to reach the body systems and begin its intended therapeutic effect.

Q: How long does the effect of a Molinar dose usually last?

The duration of the medicine's effect is typically described using pharmacokinetic data, such as its half-life and concentration profiles, as found in official documents. These measurements provide insight into how long the active substance remains active in the body following administration.

Q: Does taking Molinar make you feel tired or drowsy?

Official regulatory safety information lists all documented adverse reactions, which include nervous system effects such as somnolence (drowsiness) or fatigue. The full safety information lists these documented effects.

Q: Are there any major food or drink restrictions when taking Molinar?

The official administration instructions specify if any major food or drink restrictions exist beyond the basic instructions for taking the medicine. These restrictions are established if a substance, like grapefruit juice, is known to create an interaction that could alter the medicine's effectiveness or safety profile.

Q: Can Molinar be taken at the same time as common pain relievers?

Official regulatory documents detail known drug-drug interactions with other pharmacological classes. Official information is available to inform the assessment of potential overlap with other known restricted classes.

Q: Is Molinar known to interact with birth control pills?

Official labeling specifies all documented drug-drug interactions, which includes any known effects on the metabolism or efficacy of hormonal contraceptives. This information is provided to ensure compliance with any mandated use of effective contraception during treatment.

Q: Is Molinar considered a high-risk medication?

Regulatory documents do not categorize the medicine with subjective terms like 'high-risk.' Instead, they provide a factual profile based on documented severe adverse events, warnings, and restrictions to inform healthcare decisions. The official labeling describes the drug’s risk profile by detailing all known safety measures.

Q: Will I need regular blood tests while using Molinar?

Official regulatory documentation details any mandated monitoring requirements, which may include periodic blood tests during the course of treatment. These tests are typically required to track the drug's effect on the body, such as mineral levels or organ function.

Q: Do older adults (seniors) need a different approach to using Molinar?

The official product labeling includes a dedicated section for use in specific populations, such as the geriatric population (older adults). This section indicates whether special monitoring, dose adjustments, or additional precautions are necessary for this age group.

Q: Are the research studies on Molinar still ongoing?

Official trial registries maintained by government health bodies can be consulted to determine the status of Molinar's clinical studies. These registries track whether research is currently ongoing, open for enrollment, or has been recently completed.

Q: Is Molinar a brand name or a generic drug?

Government agencies like the FDA and NIH maintain databases that formally link the trade name of the medicine to its active ingredient(s) and chemical name. The active substance itself is defined by its generic name in official documents.

Q: How long can a person typically stay on Molinar treatment?

Official regulatory labeling explicitly defines the authorized or recommended duration of use for the medicine. This may be a strict, short-term treatment cycle or a long-term maintenance protocol, depending on the specific product's indication.

Q: Does Molinar have any potential withdrawal effects if stopped suddenly?

Regulatory documents address the possibility of withdrawal symptoms or specific rebound effects associated with stopping the medicine suddenly. The official instructions contain guidance on how treatment cessation, when required, should be approached.

Q: Is there a risk of developing a tolerance to Molinar over time?

Official labeling documents address whether the medicine has demonstrated a risk of tolerance. Tolerance is when the body may adapt to the drug, potentially requiring a higher dose to achieve the same effect over time.

Q: Can Molinar affect my ability to drive or operate machinery?

Regulatory documents include specific warnings or advice regarding documented side effects, such as dizziness or drowsiness, that could potentially impair the ability to safely drive or operate heavy machinery. This information is based on formal safety assessments.

Q: What should I do if a side effect of Molinar does not go away?

Official patient information generally includes instructions on when to contact a healthcare provider regarding any non-serious, concerning, or persistent side effects. The official information provides guidance on circumstances where a persistent symptom warrants professional medical attention.

Q: Does alcohol change how Molinar works in the body?

Regulatory information specifically addresses potential interactions or known effects associated with the use of alcohol during the treatment period. This detail is based on whether alcohol alters the metabolism or increases the risk of specific adverse reactions.

Q: What does 'contraindication' mean in the context of Molinar?

Contraindication is a formal term used in official documents to describe a condition or circumstance that makes the use of the medicine potentially harmful. Regulatory-affiliated resources often define this term as a situation where the drug is officially restricted or prohibited.

Q: Does Molinar contain any ingredients that cause common allergies?

Official labeling includes a complete, regulated list of all inactive ingredients, which are substances added to the product for stability or formulation. This list enables the identification of known allergens present in the medicine.

Q: Is it true that Molinar can cause changes in mood?

Official safety information lists all documented adverse reactions and is organized by the body system affected, including any documented effects on psychiatric or mood-related functions. The full safety profile contains this information.

Q: Can Molinar affect my weight?

Regulatory safety documentation lists adverse reactions that include any documented effects on appetite, metabolism, or changes in body weight that were reported during clinical trials.

Q: Are there known interactions between Molinar and herbal supplements?

Regulatory documents explicitly address known interactions with various substances, including botanical or herbal supplements that are known to affect how the body processes medications.

Q: What is the role of the inactive ingredients in Molinar?

The role of inactive ingredients (excipients) is documented in the official formulation description. These ingredients are used to help ensure the drug's stability, aid in proper absorption, or maintain the integrity of the tablet or capsule.

Q: Has Molinar been approved in countries outside the US?

The approval status of the medicine in other major global regions is tracked and documented by the respective governmental health agencies, such as the EMA or Health Canada.

Q: Is Molinar chemically related to any older medications?

Official regulatory information provides the medicine's chemical classification and mechanism of action. This factual detail establishes its relationship to other compounds and drug families, placing it within the pharmaceutical landscape.

Q: What distinguishes Molinar's mechanism from similar drugs?

The official Clinical Pharmacology section details the medicine's specific mechanism of action, such as its effects on certain enzymes or cellular messengers. This factual description serves as the basis for understanding how its action differs from other drug types.

Q: Can Molinar be used alongside common multivitamins?

Regulatory sources warn against co-administration with other high-level Vitamin D or calcium/phosphate supplements. This warning informs the use of multivitamins, as they often contain these restricted substances.

Q: Does Molinar carry a boxed warning from regulatory agencies?

Regulatory documents explicitly state whether the medicine has been assigned a Boxed Warning by the regulatory agency. This is a prominent warning reserved for serious risks that may lead to death or serious injury.

Q: Is Molinar a controlled substance?

Government agencies responsible for drug scheduling determine whether a medicine is classified as a controlled substance. This classification is assigned based on the medicine's potential for abuse or dependence.

Q: Can a person stop using Molinar once their symptoms improve?

Official labeling outlines the full treatment course, which may include a transition from an initial treatment phase to a prolonged maintenance phase. This suggests the treatment duration is often planned regardless of early symptom improvement.

Q: Are there any specific populations where Molinar's effects are less studied?

Regulatory documentation often details which specific populations, such as those with certain comorbidities or specific age groups, were underrepresented or excluded from the initial clinical trials. This information is used to assess the certainty of the evidence for certain groups.

Q: Do people with chronic conditions need special monitoring when taking Molinar?

Regulatory sources explicitly list chronic conditions that require additional caution or heightened monitoring during the use of the medicine. This is because these conditions may alter how the medicine works in the body or increase risk.

Q: Is Molinar linked to any effects on blood pressure?

Official regulatory documents list adverse reactions that include any documented clinical effects on blood pressure. Additionally, the mechanism of action, such as the promotion of vasodilation (blood vessel relaxation), is described.

Q: Can I crush or split my Molinar tablet?

Official administration instructions specify whether the medicine's dosage form, such as a tablet or capsule, must be swallowed whole or if it is authorized to be split or crushed. This is often crucial for the stability or proper release of the drug.

Q: What is the difference between the maximum recommended use conditions and the standard ones for Molinar?

Regulatory documents define the specific dosing regimens required for different conditions, such as the intensive initial loading phase versus a lower-dose, long-term maintenance phase. These documents also specify the established maximum dose authorized for use.

Q: Does the time of day I take Molinar matter?

Official instructions address specific timing requirements for administration, such as whether the medicine must be taken with food, or if a particular time of day is required for optimal absorption or efficacy.

Q: What is the half-life of Molinar?

The half-life is a specific pharmacokinetic value that is documented in the Clinical Pharmacology section of the official regulatory information. This measurement indicates how long it takes for half of the active substance to be cleared from the body.

Q: Are there any known long-term side effects associated with Molinar?

The official safety profile includes data from long-term clinical studies and post-marketing surveillance. This information documents adverse events that may be associated with prolonged or extended use of the medicine.

Q: Does Molinar interact with grapefruit juice?

Regulatory documents explicitly address known interactions with specific food components, such as grapefruit juice, which can significantly affect the metabolism of certain drugs. This information is included if the substance is known to significantly alter how the medicine works.

How should Molinar be stored and disposed of?

The official storage and disposal requirements for Molinar (Colecalciferol) are defined by government labeling to ensure product stability and safety.

Storage Requirements

Molinar must be stored at a controlled room temperature, typically below 25°C or 30°C, as specified on the package. The medicine must be kept in its original outer carton to protect it from light and moisture, and the container should be kept tightly closed. It is mandatory to keep Molinar out of the sight and reach of children and to do not freeze the product. For liquid drops, observe the labeled shelf-life after first opening (e.g., 4 to 8 weeks).

Disposal Instructions

Any unused or expired Molinar must not be thrown away with household waste or wastewater. Dispose of the product in accordance with local requirements, such as returning it to a pharmacy or using a pharmaceutical take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Molinar found in:

A-Z Index: